BeiGene's Q4 revenue increased by 33% year-on-year, turned profitable for the full year, Brukinsa achieved a record high with 1.1 billion in a single quarter | Earnings Report Insights

```

BeiGene announced its financial results for the fourth quarter and full year of 2025 on February 26, crossing the breakeven point and bidding farewell to years of "burning cash."

Total annual revenue reached $5.343 billion, up 40% year-on-year; fourth quarter total revenue was $1.5 billion, up 33% year-on-year.GAAP net profit for 2025 was $287 million, marking a turnaround from the $645 million net loss in 2024 and achieving historical profitability.

The flagship product Brukinsa (Zebutinib) continued its rapid expansion, with a global annual sales of $3.9 billion, up 49% year-on-year; fourth quarter sales surpassed $1.1 billion, up 38% year-on-year. The US market contributed $2.8 billion for the year, up 45% year-on-year, firmly holding the number one position in the global BTK inhibitor market.

Profit quality surged dramatically, with annual non-GAAP operating profit reaching $1.1 billion, soaring more than 23 times over 2024’s $45.36 million. Free cash flow turned positive to $942 million for the year, a qualitative leap from 2024’s negative $633 million. The full release of operating leverage signals a new stage in the company’s commercialization.

Looking ahead to 2026, the company provides total revenue guidance of $6.2 to $6.4 billion, an increase of about 20% year-on-year, and expects GAAP operating profit of $700 to $800 million. Late-stage hematology pipeline products like Sotoclaz are nearing commercialization and are set to inject the next phase of growth momentum for the company.

Core products: Brukinsa dominates the track, Baizean expands steadily

Brukinsa, leveraging extensive regulatory approvals and deep clinical data barriers, has established an absolute dominant position in the BTK inhibitor market. SEQUOIA trial six-year follow-up and ALPINE long-term follow-up data released at ASH further validated its sustained benefits in first-line and relapsed/refractory CLL/SLL patients, consolidating its leading advantage.

Baizean's global sales reached $182 million in the fourth quarter, up 18% year-on-year; annual sales were $737 million, up 19% year-on-year. Trial data showed statistically significant OS improvement in first-line treatment of HER2-positive gastroesophageal adenocarcinoma when combined with Zeniadatuximab, laying the foundation for submitting new indication applications in 2026.

Amgen-licensed products recorded annual sales of $486 million, up 33% from last year.

Pipeline progress: Sotoclaz opens the second growth curve

The BCL2 inhibitor Sotoclaz (Baoyueda) is the most significant pipeline breakthrough this quarter: It received global first approval in China, covering R/R MCL and CLL/SLL indications; simultaneously granted FDA Priority Review qualification, and EU marketing application has also been submitted.

In the first half of 2026, the FDA will make a regulatory decision on R/R MCL, and it is expected to be the next core commercial product for the company.

BTK CDAC candidate BGB-16673 released Phase 1 CLL data at ASH and is expected to submit accelerated approval application in the second half of 2026.

Several early-stage solid tumor pipeline products have launched first-in-human trials; CDK4 inhibitor BGB-43395 is planned to start a Phase 3 trial for HR+/HER2- metastatic breast cancer in the first half of 2026, continuously enriching the pipeline lineup.

Profitability: Gross margin expands, cost control shows results

GAAP gross margin for Q4 and full year 2025 were 90.4% and 87.3%, respectively, higher than 85.6% and 84.3% for the same period in 2024. Non-GAAP gross margin (excluding depreciation and amortization) were 90.7% and 87.8%, scale effect and improved manufacturing efficiency continue to be reflected in profit quality.

Full-year GAAP operating expenses were $4.227 billion, up 12% year-on-year, significantly less than the 40% growth in revenue, highlighting a notable operating leverage effect.

SG&A proportion of product revenue fell from 48% in 2024 to 39%, R&D expenses increased 10% year-on-year. Note that net profit for the year includes one-off negative factors such as $76 million equity investment impairment and $25 million non-recurring tax items.

Balance sheet and cash flow: Ammunition sufficient, confidence surges

By the end of 2025, the company's cash and cash equivalents reached $4.61 billion, up about 75% from $2.64 billion at the end of 2024, significantly strengthening financial position.

Annual net cash inflow from operating activities was $1.128 billion, a stark contrast to the net outflow of $141 million in 2024, with operating cash flow turning substantially positive for the first time.

On the balance sheet, total assets increased to $8.19 billion, and shareholders’ equity was $4.36 billion.

Due to the Royalty Pharma agreement, $907 million in future royalty fee liabilities were added. Annual capital expenditures were $186 million, significantly down from $493 million in 2024, greatly improving free cash flow quality.

2026 Guidance: Aiming for $6.4 billion, profit expansion expected

2026 full-year total revenue guidance is $6.2 to $6.4 billion, midpoint $6.3 billion, up about 18% year-on-year. GAAP gross margin is expected to remain high at around 80%, GAAP operating profit $700 to $800 million, non-GAAP operating profit $1.4 to $1.5 billion, all representing substantial expansion over 2025.

The company notes that other income (expenses) is expected to net $25 to $50 million in expenditure, relating to Royalty Pharma interest amortization.

If 2026 results provide sufficiently positive evidence, partial reversal of valuation allowances will result in significant tax benefits, though specific timing is uncertain. Diluted and outstanding ADS estimated to be around 118 million shares, roughly unchanged from current levels.

Risk Disclaimer and Limitation of LiabilityThe market is risky, investment requires caution. This article does not constitute personal investment advice nor does it take into account the specific investment objectives, financial condition, or needs of individuals. Users should consider whether any opinions, viewpoints, or conclusions herein fit their particular situation. Investment based on this is at one's own risk. ```